Our Research

Benaroya Research Institute (BRI) is on a mission to predict, prevent, reverse and cure immune system diseases. We study the cells and processes within the immune system, how and why immune system diseases start, and how to rebalance the immune system back to health. Our focus spans a wide variety of immune system diseases – including autoimmune diseases, asthma, allergy and cancer – with the goal of transforming our understanding of how to prevent and treat these conditions.

Collaboration defines our work. We build teams within our institute and with partners around the world to take on some of the most difficult questions in immunology. This approach moves us closer to our vision of a healthy immune system for everyone.

Our Centers of Discovery: A pipeline from lab research to life-changing care

BRI’s research is organized around four Centers of Discovery, allowing us to accelerate advances at every stage of our work. Our centers enable us to make discoveries in the lab and provide a foundation for new and innovative therapies. They also help us to take questions directly from the clinic — such as what makes a therapy work for one person and not another — back to our labs to find meaningful answers.

Center Preview Square Image - Fundamental Immunology

Fundamental Immunology

Examining cells, genes and molecules to better understand the immune system

Center Preview Square Image - Translational Immunology

Translational Immunology

Exploring how lab discoveries could become potential new therapies; studying how therapies alter the immune system

Center Preview Square Image - Interventional Immunology

Interventional Immunology

Using clinical trials to test and refine new and more effective therapies

Center Preview Square Image - Systems Immunology

Systems Immunology

Analyzing large and complex data sets across all Centers to identify patterns and accelerate breakthroughs

Biorepositories

Learn about this incredible asset

Join Our Research

See our list of clinical trials

Access samples for research

Our Core Labs: Building and using the latest tools and technologies

Our Core Labs enable our scientists to build and use some of the most innovative tools in immunology that allow for advanced imaging, data sequencing and exploring the human genome. Each core is led by an expert in their field. Scientists across BRI and from other institutes can partner with these experts to leverage these tools and fuel discoveries in all areas of research.

Core Preview Box - CATA

Cell and Tissue Analysis

Analyzing, sorting, selecting and identifying cells with a variety of parameters. These tools are available to scientists within BRI and to those from other institutions.

Learn about our flow cytometry, imaging and histology cores

Core Preview Box - Genomics

Genomics

Providing resources to study the structure and function of the human genome. This includes sequence analysis, from sample processing through data generation, and basic bioinformatics analysis.

Learn about our cutting edge genomics core

Core Preview Box - HIP

Human Immunophenotyping

Studying immune system diseases by helping identify underlying mechanisms of disease, developing biomarkers of disease and informing new treatments.

Our experts set us apart, learn about them

Core Preview Box - Tetramer

Tetramers

Providing MHC class II tetramer reagents, an innovative tool invented at BRI that helps scientists find and study very specific cells.

Create a tetramer with us

Featured Publications

Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes

J Clin Invest

Gabriele Sassi, Pierre Lemaitre, Laia Fernández Calvo, Francesca Lodi, Álvaro Cortés Calabuig, Samal Bissenova, Amber Wouters, Laure Degroote, Marijke Viaene, Niels Vandamme, Lauren Higdon, Peter S Linsley, S Alice Long, Chantal Mathieu, Conny Gysemans

T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes

J Immunother Cancer

Ariadna Bartoló-Ibars, Andrea Aran, Alexandra M Johansson, Valentín Ortiz-Maldonado, Nela Klein-González, Anna Alonso-Saladrigues, Eddie James, Alvaro Urbano-Ispizua, Susana Rives, Julio Delgado, Europa Azucena González-Navarro, William W Kwok, Manel Juan

ATG as disease-modifying therapy for new-onset type 1 diabetes

Lancet

A multi-omics recovery factor predicts long COVID in the IMPACC study

J Clin Invest

Gisela Gabernet, Jessica Maciuch, Jeremy P Gygi, John F Moore, Annmarie Hoch, Caitlin Syphurs, Tianyi Chu, Naresh Doni Jayavelu, David B Corry, Farrah Kheradmand, Lindsey R Baden, Rafick-Pierre Sekaly, Grace A McComsey, Elias K Haddad, Charles B Cairns, Nadine Rouphael, Ana Fernandez-Sesma, Viviana Simon, Jordan P Metcalf, Nelson I Agudelo Higuita, Catherine L Hough , William B Messer, Mark M Davis, Kari C Nadeau, Bali Pulendran, Monica Kraft, Chris Bime, Elaine F Reed, Joanna Schaenman, David J Erle, Carolyn S Calfee, Mark A Atkinson, Scott C Brakenridge, Esther Melamed, Albert C Shaw, David A Hafler, Alison D Augustine , Patrice M Becker, Al Ozonoff, Steven E Bosinger, Walter Eckalbar, Holden T Maecker, Seunghee Kim-Schulze, Hanno Steen, Florian Krammer, Kerstin Westendorf, IMPACC Network, Bjoern Peters, Slim Fourati, Matthew C Altman, Ofer Levy, Kinga K Smolen, Ruth R Montgomery, Joann Diray-Arce, Steven H Kleinstein, Leying Guan, Lauren I R Ehrlich

Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma

Nat Commun

Courtney L Gaberino, R Max Segnitz, Kimberly A Dill-McFarland, Leonard B Bacharier, Agustin Calatroni, Michelle A Gill, Jeffrey Stokes, Andrew H Liu , Robyn T Cohen, Rajesh Kumar, Abigail Lang, Gurjit K Khurana Hershey, Michael G Sherenian, Edward M Zoratti, Stephen J Teach, Meyer Kattan , Patrice M Becker, Alkis Togias, William W Busse, Daniel J Jackson, Matthew C Altman